Mains issueGS-3News & Analysis24 October 2026

Global Health Security and Vaccine Development for Emerging Epidemics

Aspirants should be able to analyze the multi-faceted challenges and collaborative scientific efforts required for global health security, particularly in developing and deploying vaccines against emerging infectious diseases, while considering ethical and equitable access dimensions.

Source: thehindu.comOriginal report

Understand the issue · 1/2

Why now

The commencement of the Tumaini clinical trial for an Ebola vaccine in the Democratic Republic of Congo highlights ongoing global efforts to combat emerging infectious diseases and the critical role of advanced vaccine technologies in public health preparedness. This issue is crucial for Mains as it exemplifies challenges in epidemic response, international collaboration, and the ethical considerations in vaccine development.

Core issue

The first clinical trial for an Ebola vaccine targeting the Bundibugyo strain, named Tumaini, has commenced in the Democratic Republic of Congo (DRC). Led by the DRC with support from the World Health Organisation (WHO), the trial initially tests the existing Ervebo vaccine (approved for the Zaire strain) for cross-protection. It will later incorporate two Bundibugyo-specific candidate vaccines developed by the University of Oxford (ChAdOx1 adenoviral vector) and Moderna (mRNA technology), both funded by CEPI. The trial employs a ring vaccination approach and includes pregnant women and children to generate comprehensive evidence for future outbreak preparedness.

Continue this issue

Turn the issue into an answer.

Unlock the issue map, answer-use material, grounded Mains PYQ connections and writing practice.

Unlock Mains Current Affairs